-
公开(公告)号:US20110190237A1
公开(公告)日:2011-08-04
申请号:US12861806
申请日:2010-08-23
申请人: James Heck , Nicolas Winssinger , John C. Chabala , Sofia Barluenga , Ruihong Chen , Allan Rubenstein , Jin-Chen Yu
发明人: James Heck , Nicolas Winssinger , John C. Chabala , Sofia Barluenga , Ruihong Chen , Allan Rubenstein , Jin-Chen Yu
IPC分类号: A61K31/675 , C07F9/58 , C07F9/59 , A61P9/00 , A61P29/00 , A61P35/00 , A61P25/00 , A61P11/06 , C12N5/09
CPC分类号: C07F9/65586 , A61K31/675 , C07F9/58 , C07F9/59
摘要: The present invention includes macrocyclic prodrug compounds, pharmaceutical compositions containing them. The present invention also includes use of these compounds in the treatment of various diseases including an autoimmune disease, an inflammatory disease, a neurological or neurodegenerative disease, cancer, a cardiovascular disease, allergy, asthma, a hormone-related disease, and tumors or symptoms resulting from neurofibromatosis.
摘要翻译: 本发明包括大环前药化合物,含有它们的药物组合物。 本发明还包括这些化合物在治疗各种疾病中的应用,包括自身免疫性疾病,炎性疾病,神经性或神经退行性疾病,癌症,心血管疾病,变态反应,哮喘,激素相关疾病和肿瘤或症状 由神经纤维瘤病引起。
-
公开(公告)号:US07763628B2
公开(公告)日:2010-07-27
申请号:US11788039
申请日:2007-04-17
IPC分类号: A61K31/517 , C07D239/72
CPC分类号: C07D239/90 , C07D239/91
摘要: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
摘要翻译: 公开了式1a,1b,1c和1d的喹唑啉酮。 它们可用于治疗与KSP驱动蛋白活性相关的细胞增殖性疾病和病症。
-
公开(公告)号:US20100063073A1
公开(公告)日:2010-03-11
申请号:US12547390
申请日:2009-08-25
IPC分类号: A61K31/517 , A61P35/00
CPC分类号: C07D239/90 , C07D239/91
摘要: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
摘要翻译: 公开了式1a,1b,1c和1d的喹唑啉酮。 它们可用于治疗与KSP驱动蛋白活性相关的细胞增殖性疾病和病症。
-
24.
公开(公告)号:US5140030A
公开(公告)日:1992-08-18
申请号:US569257
申请日:1990-08-16
IPC分类号: C07D477/22 , C07F9/6561
CPC分类号: C07F9/65611 , C07D477/22 , Y02P20/55
摘要: Disclosed are 2-aza-substituted 1-carbadethiapen-2-em-3-carboxylic acids. I, where the generic 2-aza group includes azido, acylamino, amino, alkylamino, dialkylamino, triazolyl, triazolinyl, aziridinyl, and their pharmaceutically acceptable salt, ester, anhydride and amide derivatives which are useful as antibiotics. Also disclosed are processes for the preparation of I from the known, appropriately substituted bicyclic keto ester II via the 2-azido central intermediate III: ##STR1## wherein R.sup.16 is H or CH.sub.3, preferably beta-methyl; R.sup.6, and R.sup.7 are independently hydrogen, linear, branched or cyclic C.sub.1 -C.sub.5 alkyl, which can be substituted with fluoro, hydroxy, protected hydroxy, sulfoxy, amino, protected amino, wherein R.sup.6 and R.sup.7 taken together can also be C.sub.2 -C.sub.4 alkylidene, similarly substituted; with the proviso that both R.sup.6 and R.sup.7 are not unsubstituted alkyl, R.sup.1 and R.sup.2 are, inter alia, hydrogen, alkyl, acyl, and can be joined to form a ring comprising 3 to 7 atoms; R.sup.a is hydrogen, a salt cation, a removable protecting group, or a pharmaceutically acceptable ester moiety.Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.
摘要翻译: 披露的是2-氮杂取代的1-碳代萘二烯-2-烯-3-羧酸。 I,其中通用2-氮杂基团包括可用作抗生素的叠氮基,酰氨基,氨基,烷基氨基,二烷基氨基,三唑基,三唑啉基,氮丙啶基及其药学上可接受的盐,酯,酸酐和酰胺衍生物。 还公开了通过2-叠氮中心中间体III从已知的适当取代的双环酮酯II制备I的方法:其中R 16是H或CH 3,优选β- 甲基; R 6和R 7独立地是氢,直链,支链或环状的C 1 -C 5烷基,其可以被氟,羟基,保护的羟基,亚磺氧基,氨基,保护的氨基取代,其中R 6和R 7一起也可以是C 2 -C 4亚烷基, 同样取代; 条件是R6和R7都不是未取代的烷基,R1和R2特别是氢,烷基,酰基,并且可以连接形成包含3至7个原子的环; Ra是氢,盐阳离子,可除去的保护基或药学上可接受的酯部分。 还公开了制备这些化合物的方法; 包含这些化合物的药物组合物; 和治疗方法,包括当指出抗生素效应时施用这些化合物和组合物。
-
公开(公告)号:US5120729A
公开(公告)日:1992-06-09
申请号:US540992
申请日:1990-06-20
申请人: John C. Chabala , Michael N. Chang , Yuan-Ching P. Chiang , James V. Heck , Kathryn L. Thompson , Shu S. Yang
发明人: John C. Chabala , Michael N. Chang , Yuan-Ching P. Chiang , James V. Heck , Kathryn L. Thompson , Shu S. Yang
IPC分类号: A61K31/395 , A61K31/397 , A61P3/06 , A61P9/10 , A61P43/00 , C07D205/08 , C12N9/99
CPC分类号: C07D205/08
摘要: This application relates to compounds of formula (I), which are useful as antihypercholesterolemic agents. ##STR1##
-
26.
公开(公告)号:US4783453A
公开(公告)日:1988-11-08
申请号:US97348
申请日:1987-09-08
IPC分类号: C07D477/22 , C07F9/6561 , C07D487/04 , A61K31/40
CPC分类号: C07D477/22 , C07F9/65611 , Y02P20/55
摘要: Disclosed are 2-aza-substituted 1-carbadethiapen-2-em-3-carboxylic acids I, where the generic 2-aza group includes azido, acylamino, amino, alkylamino, dialkylamino, triazolyl, triazolinyl, aziridinyl, and their pharmaceutically acceptable salt, ester, anhydride and amide derivatives which are useful as antibiotics. Also disclosed are processes for the preparation of I from the known, appropriately substituted bicyclic keto ester II via the 2-azido central intermediate III: ##STR1## wherein R.sup.16 is H or CH.sub.3, preferably beta-methyl; R.sup.6, and R.sup.7 are independently hydrogen, linear, branched or cyclic C.sub.1 -C.sub.5 alkyl, which can be substituted with fluoro, hydroxy, protected hydroxy, sulfoxy, amino, protected amino, wherein R.sup.6 and R.sup.7 taken together can also be C.sub.2 -C.sub.4 alkylidene, similarly substituted; with the proviso that both R.sup.6 and R.sup.7 are not unsubstituted alkyl, R.sup.1 and R.sup.2 are, inter alia, hydrogen, alkyl, acyl, and can be joined to form a ring comprising 3 to 7 atoms; R.sup.a is hydrogen, a salt cation, a removable protecting group, or a pharmaceutically acceptable ester moiety.Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.
摘要翻译: 披露的是2-氮杂取代的1-碳代萘二甲酸-2-烯-3-羧酸I,其中通用的2-氮杂基团包括叠氮基,酰氨基,氨基,烷基氨基,二烷基氨基,三唑基,三唑基,氮丙啶基及其药学上可接受的盐 ,可用作抗生素的酯,酸酐和酰胺衍生物。 还公开了通过2-叠氮中心中间体III从已知的适当取代的双环酮酯II制备I的方法:其中R 16是H或CH 3,优选β- 甲基; R 6和R 7独立地是氢,直链,支链或环状的C 1 -C 5烷基,其可以被氟,羟基,保护的羟基,亚磺氧基,氨基,保护的氨基取代,其中R 6和R 7一起也可以是C 2 -C 4亚烷基, 同样取代; 条件是R6和R7都不是未取代的烷基,R1和R2特别是氢,烷基,酰基,并且可以连接形成包含3至7个原子的环; Ra是氢,盐阳离子,可除去的保护基或药学上可接受的酯部分。 还公开了制备这些化合物的方法; 包含这些化合物的药物组合物; 和治疗方法,包括当指出抗生素效应时施用这些化合物和组合物。
-
27.
公开(公告)号:US4659720A
公开(公告)日:1987-04-21
申请号:US551150
申请日:1983-11-16
IPC分类号: C07D233/90 , C07D401/04 , A61K31/44 , A61K31/47 , C07D401/06
CPC分类号: C07D401/04 , C07D233/90
摘要: 5-Amino or substituted amino imidazoles are disclosed as having anticoccidial activity. The compounds are useful for controlling cecal and or intestinal coccidiosis when administered in minor quantitites to animals, in particular to poultry, usually in admixture with animal sustenance.
摘要翻译: 5-氨基或取代的氨基咪唑被公开为具有抗球虫活性。 当以较小的量给予动物,特别是通常与动物饲养物混合的家禽时,这些化合物可用于控制盲肠和/或肠球虫病。
-
公开(公告)号:US08658656B2
公开(公告)日:2014-02-25
申请号:US13612677
申请日:2012-09-12
IPC分类号: A01N43/54 , A61K31/517 , C07D419/00 , C07D239/72
CPC分类号: C07D239/90 , C07D239/91
摘要: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
摘要翻译: 公开了式1a,1b,1c和1d的喹唑啉酮。 它们可用于治疗与KSP驱动蛋白活性相关的细胞增殖性疾病和病症。
-
公开(公告)号:US08008311B2
公开(公告)日:2011-08-30
申请号:US12704411
申请日:2010-02-11
IPC分类号: A01N43/90 , A61K31/617 , C07D239/72 , C07D419/00
CPC分类号: C07D239/90 , C07D239/91
摘要: Quinazolinones of formulae (a, b, c and d) are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
摘要翻译: 公开了式(a,b,c和d)的喹唑啉酮。 它们可用于治疗与KSP驱动蛋白活性相关的细胞增殖性疾病和病症。
-
公开(公告)号:US07589098B2
公开(公告)日:2009-09-15
申请号:US11084787
申请日:2005-03-21
IPC分类号: A61K31/517 , C07D239/88 , C07D401/12 , C07D403/12
CPC分类号: C07D239/90 , C07D239/91
摘要: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
摘要翻译: 公开了式1a,1b,1c和1d的喹唑啉酮。 它们可用于治疗与KSP驱动蛋白活性相关的细胞增殖性疾病和病症。
-
-
-
-
-
-
-
-
-